Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
CompletedNot applicableNCT03082261
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
The TRIUMPH study is a post-market, international, multicenter, interventional, prospective, single-arm study intended to evaluate the sustainability of pain control and psychosocial and functional responses utilizing a multiple-waveform enabled neurostimulator in subjects with chronic, intractable pain of the trunk and/or limbs.
Study details
- Official title
- Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator
- Conditions
- Chronic Pain
- Intractable Pain
- Interventions
- Device: Prodigy, Prodigy MRI or Proclaim Elite IPG
- Sponsor
- Abbott Medical Devices
- Start date
- 2017-03-03
- Primary completion
- 2019-01-24
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Canada, Finland, Germany, Italy, Spain, Switzerland, United States
- Total sites listed
- 22
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Subject has chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome and intractable low back and leg pain. 2. Subject has a score of 6 or higher on the numeric rating scale (NRS) for average pain specific to the area(s) of chronic pain being treated over the past 24 hours at the baseline visit. 3. Subject is considered by the Investigator as a candidate for implantation of a spinal cord stimulator system according to the system Instructions For Use. 4. Subject is 18 years of age or older at the time of enrollment. 5. Subject is willing to cooperate with the study requirements including compliance with the regimen and completion of all study visits. 6. Subject has signed and received a copy of the Ethics Committee/Institutional Review Board (EC/IRB) approved informed consent. Exclusion Criteria: 1. Subject currently has a spinal cord stimulation system implanted. 2. Subject has previously failed spinal cord stimulation (SCS) therapy (either trial system evaluation or permanent implant). 3. Subject has a primary diagnosis of Peripheral Vascular Disease (PVD), Angina Pectoris, or Chronic Migraine. 4. Subject has or plans to have a Peripheral Nerve Stimulation system (PNS), Peripheral Nerve field Stimulation system (PNfS), Dorsal Root Ganglion system (DRG), or implantable infusion pump. 5. Subject is currently participating in another clinical investigation with an active treatment arm. 6. Subject unable to read and/or write.
Canadian sites (2)
| Facility | City | Province |
|---|---|---|
| CHA L'Enfant Jesus | Québec | |
| Royal University Hospital | Saskatoon | Saskatchewan |
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03082261